Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
24,750
+100 (0.41%)
Aug 14, 2025, 3:30 PM KST
0.41%
Market Cap272.72B
Revenue (ttm)29.43B
Net Income (ttm)4.57B
Shares Out11.06M
EPS (ttm)n/a
PE Ratio59.66
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume135,559
Average Volume170,279
Open24,550
Previous Close24,650
Day's Range24,500 - 25,250
52-Week Range12,550 - 30,750
Betan/a
RSI47.96
Earnings DateAug 8, 2025

About Accolade

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.